| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
Cancer Immunology Program, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, Illinois 60153
To identify genes that are differentially up-regulated in prostate cancer of transgenic adenocarcinoma mouse prostate (TRAMP) mice, we subtracted cDNA isolated from mouse kidney and spleen from cDNA isolated from TRAMP-C1 cells, a prostate tumor cell line derived from a TRAMP mouse. Using this strategy, cDNA clones that were homologous to human six-transmembrane epithelial antigen of the prostate (STEAP) and prostate stem cell antigen (PSCA) were isolated. Mouse STEAP (mSteap) is 80% homologous to human STEAP at both the nucleotide and amino acid levels and contains six potential membrane-spanning regions similar to human STEAP. Mouse PSCA (mPsca) shares 65% homology with human PSCA at the nucleotide and amino acid levels. mRNA expression of mSteap and mPsca is largely prostate-specific and highly detected in primary prostate tumors and metastases of TRAMP mice. Both mSteap and mPsca map to chromosome 5. Another known gene coding for mouse prostate-specific membrane antigen (mPsma) is also highly expressed in both primary and metastatic lesions of TRAMP mice. These results indicate that the TRAMP mouse model can be used to effectively identify genes homologous to human prostate-specific genes, thereby allowing for the investigation of their functional roles in prostate cancer. mSteap, mPsca, and mPsma constitute new tools for preventative and/or therapeutic vaccine construction and immune monitoring in the TRAMP mouse model that may provide insights into the treatment of human prostate cancer.
This article has been cited by other articles:
|
|
 |
|
  M. Fasso, R. Waitz, Y. Hou, T. Rim, N. M. Greenberg, N. Shastri, L. Fong, and J. P. Allison SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade PNAS, March 4, 2008; 105(9): 3509 - 3514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. de la Luz Garcia-Hernandez, A. Gray, B. Hubby, O. J. Klinger, and W. M. Kast Prostate Stem Cell Antigen Vaccination Induces a Long-term Protective Immune Response against Prostate Cancer in the Absence of Autoimmunity Cancer Res., February 1, 2008; 68(3): 861 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. d. l. L. Garcia-Hernandez, A. Gray, B. Hubby, and W. M. Kast In vivo Effects of Vaccination with Six-Transmembrane Epithelial Antigen of the Prostate: A Candidate Antigen for Treating Prostate Cancer Cancer Res., February 1, 2007; 67(3): 1344 - 1351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Ohgami, D. R. Campagna, A. McDonald, and M. D. Fleming The Steap proteins are metalloreductases Blood, August 15, 2006; 108(4): 1388 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Rodeberg, R. A. Nuss, S. F. Elsawa, and E. Celis Recognition of Six-Transmembrane Epithelial Antigen of the Prostate-Expressing Tumor Cells by Peptide Antigen-Induced Cytotoxic T Lymphocytes Clin. Cancer Res., June 15, 2005; 11(12): 4545 - 4552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Yu. Nikitina, S. A. Desai, X. Zhao, W. Song, A. Z. Luo, R. D. Gangula, K. M. Slawin, and D. M. Spencer Versatile Prostate Cancer Treatment with Inducible Caspase and Interleukin-12 Cancer Res., May 15, 2005; 65(10): 4309 - 4319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Tran, C. Lin, J. Yamashiro, and R. E. Reiter Prostate Stem Cell Antigen Is a Marker of Late Intermediate Prostate Epithelial Cells Mol. Cancer Res., December 1, 2002; 1(2): 113 - 121. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
